REGiMMUNE Corporation announced today that it has appointed Mr. Kohtaro Toda as a board member. He is currently an investment manager of Japan Asia Investment Co., Ltd. (JAIC), a Japanese venture capital firm with $1 billion under management. The addition of this new management position reflects the company’s continued progress into a clinical stage company, and comes as REGiMMUNE prepares for major development milestones including the establishing PoC for its lead compound, RGI-2001, for prevention of graft-versus-host disease (GvHD), expected to be completed in the first half of 2013.
